Pressmeddelande -

Tataa Biocenter new majority shareholder in Life Genomics

Tataa Biocenter has made agreement with Bure Equity and ALMI Invest to acquire all their shares in Life Genomics. After completed transaction Tataa Biocenter will hold 59 % of the shares.

Life Genomics started as spin-off from Tataa Biocenter in 2014 and is Sweden’s leading genetic testing company offering non-invasive prenatal testing (NIPT) to pregnant women, carrier test to those planning family, and risk test for Alzheimer’s disease. The laboratory is located in Göteborg Sweden and is accredited according to ISO 15189. It analyzes samples primarily from Sweden, and expands internationally currently accepting samples from some 10 countries.

Tataa Biocenter was founded in 2001 by researchers at Chalmers University. Tataa offers molecular analyses to industry and have at multiple occasions been nominated Europe’s prime laboratory in its field. Tataa has developed the techniques Two-Tailed PCR and Direct Blood Genotyping (DBG) based on which several products have been developed.

During the pandemic Tataa was on February 3 among the first laboratories in Europe to offer PCR test for SARS-CoV-2. The TATAA GrandPerformance SARS-CoV-2 Detection kit was registered for the CE-IVD mark and the laboratory was equipped for SARS-CoV-2 analysis. A network of private care givers has been established covering Sweden from Kiruna in the north to Malmö in the south around the platform www.coronapassport.se offering travelers covid-19 tests and fit-for-flight certificates with short turn-around-time.

Tataa also supports the Swedish public testing.

”It has been an exciting and successful journey this far together with ALMI Invest and Bure Equity, who provided the means to bring Life Genomics into next phase, where we see synergy between TATAA Biocenters covid testing business offered through the Coronapassport platform and Life Genomics’s offerings through the NIPT and Fostertest platforms. The future is bright!” - Mikael Kubista, CEO, Tataa Biocenter.

”Life Genomics has shown strong development during the period we have been active, in particular the most recent years Life Genomics management and employees have grown the company while maintaining profitability – impressive accomplishment for a young company. We are glad to see that Life Genomics with Tataa as majority shareholder will have excellent opportunity for further growth around the new platforms” - Louise Warme (ALMI Invest) och Sophie Hagströmer (Bure Equity)

“We thank ALMI Invest and Bure Equity for their contributions. Their financial support and active and focused work in the board has been essential to Life genomics successful development. It is a natural step for us to continue international growth with support from Tataa Biocenter with their competence and network” - Göran Jacobsson, CEO Life Genomics

Relaterade länkar

Ämnen

  • Epidemier

Kategorier

  • #covid-19
  • #tataa
  • #qpcr
  • #corona
  • #coronapassport
  • #lifegenomics
  • #covid19
  • #sars-cov-2
  • #covid
  • #test
  • #nipt

TATAA Biocenter grundades 2001 kring avancerad forskning och utveckling inom bioteknik vid Chalmers Tekniska högskola och utvecklar ultrakänsliga molekylära analysmetoder baserade på den skyddade tekniken Two-Tailed PCR. Genom avknoppningen Life Genomics erbjuds genetiska tester såsom icke-invasiv fosterdiagnostik, s.k. NIPT. Tidigare i år utsågs TATAA Biocenter till Europas främsta genanalysföretag av Global Health & Pharma

TATAA Biocenter var bland de första att utveckla ett test för SARS-COV-2, som registrerats för CE-IVD under namnet TATAA GrandPerformance SARS-COV-2 Detection kit för diagnostisk användning inom Europa. TATAA var också tidigt igång med testning för SARS-COV-2 i samarbete med Saint James Hospital på Malta. I Sverige erbjuder TATAA Biocenter testning till resenärer genom plattformen www.coronapassport.se samt bidrar till den offentliga screeningen inom Västra Götalandsregionen. 

Kontakter

Relaterat innehåll

  • TATAA Biocenter named “Best Nucleic Acid Analysis Service Provider in Europe” by Global Health & Pharma

    Global Health & Pharma, a British information platform supporting a community of over 250,000 in the health, veterinary and environmental areas, has named Swedish service provider TATAA Biocenter AB “Best Nucleic Acid Analysis Service Provider in Europe”.
    “We are excited at being the no.1 service provider in Europe. This shows our focus on delivering highest quality results based on careful

  • Alu-assay tool for quality assessment in single cell and cell-free DNA analysis

    Most PCR reagents, including master mixes, primer and probe solutions, and buffers, are contaminated with residual human genomic DNA (gDNA). For measurements on conventional samples the contamination is negligible, but it can be very important, even detrimental, in single cell and rare mutation analyses. To test the purity of reagents TATAA Biocenter has developed ultra-sensitive qPCR assays targe

  • TATAA Biocenter and BTU develops Two-tailed PCR for microRNA analysis offering superior sensitivity and specificity.

    TATAA Biocenter and the Institute of Biotechnology, BIOCEV, have developed Two-Tailed PCR for ultrasensitive analysis of microRNAs based on products from Roche. Based on an innovative novel design with a RT primer sensing the microRNA using two connected hemi-probes exceeding sensitivity and superior specificity is achieved. The results of the work appeared in this week’s issue of the prestigious

  • Frost & Sullivan Recognizes TATAA Biocenter's Complete, Best-in-Class Services for Analyzing Genetic Material

    LONDON, Aug. 20, 2013 /PRNewswire/ -- Based on its recent research on the gene expression profiling services market, Frost & Sullivan presents TATAA Biocenter with the 2013 European Frost & Sullivan Award for Customer Value Leadership. TATAA Biocenter offers an end-to-end range of services for analyzing genetic material, from quantitative reverse transcription polymerase chain reaction (qR